Integra Lifesciences Holdings Corp Stock Upgraded (IART)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Integra Lifesciences Holdings (Nasdaq: IART) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • IART's revenue growth has slightly outpaced the industry average of 8.7%. Since the same quarter one year prior, revenues rose by 12.6%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • Powered by its strong earnings growth of 200.00% and other important driving factors, this stock has surged by 27.89% over the past year, outperforming the rise in the S&P 500 Index during the same period. Turning to the future, naturally, any stock can fall in a major bear market. However, in almost any other environment, the stock should continue to move higher despite the fact that it has already enjoyed nice gains in the past year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 217.4% when compared to the same quarter one year prior, rising from $1.52 million to $4.83 million.
  • Net operating cash flow has significantly increased by 461.24% to $16.38 million when compared to the same quarter last year. In addition, INTEGRA LIFESCIENCES HLDGS has also vastly surpassed the industry average cash flow growth rate of 1.59%.
  • The gross profit margin for INTEGRA LIFESCIENCES HLDGS is rather high; currently it is at 69.50%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 2.08% trails the industry average.

If you liked this article you might like

Johnson & Johnson Signals It Could Make Additional Divestitures

Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

Derma Sciences Soars Almost 40% on Buyout by Integra